CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

T cells sit at the center of modern immunotherapy, yet many of the rules that govern their activation, differentiation, dysfunction (e.g., exhaustion), and ...

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...

Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the ...

"Why do immune cells that are supposed to eliminate viruses suddenly turn against our own body?" There are instances where killer T cells—which are meant to precisely remove virus-infected ...